Rgls4326 (DrugBank: -)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 67 | Polycystic kidney disease | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04536688 (ClinicalTrials.gov) | October 2020 | 24/8/2020 | A Study of RGLS4326 in Patients With Autosomal Dominant Polycystic Kidney Disease | A Phase 1b, Multicenter, Open-Label, Adaptive Design Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RGLS4326 Administered Via SC Injection to Patients With Autosomal Dominant Polycystic Kidney Disease | Polycystic Kidney Disease, Autosomal Dominant | Drug: RGLS4326 | Regulus Therapeutics Inc. | NULL | Recruiting | 18 Years | 70 Years | All | 27 | Phase 1 | United States |